Antonio Bertolotto
Overview
Explore the profile of Antonio Bertolotto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
139
Citations
1923
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Montarolo F, Thielens S, Bove M, Bertolotto A, Tempia F, Hoxha E
Mol Neurobiol
. 2025 Mar;
PMID: 40055293
The transcription factor NUclear Receptor Related 1 (NURR1) regulates the development and maintenance of midbrain dopaminergic (mDA) neurons, which control voluntary movement, motivation, and reward. NURR1 also plays anti-inflammatory functions...
2.
Malucchi S, Bava C, Valentino P, Martire S, Lo Re M, Bertolotto A, et al.
J Neurol
. 2024 Sep;
271(12):7494-7501.
PMID: 39313638
Background: Neurofilament light chain (NFL) is a neuroaxonal cytoskeletal protein released into cerebrospinal fluid (CSF) and eventually into blood upon neuronal injury. Its detection in serum (sNFL) makes it a...
3.
Bava C, Valentino P, Malucchi S, Bottero R, Martire S, Di Sapio A, et al.
Mult Scler Relat Disord
. 2024 Jul;
88:105748.
PMID: 38959590
Background: In the field of research for new validated surrogate biomarkers of treatment efficacy, disease activity and progression in Multiple Sclerosis (MS), serum neurofilament light-chain (sNFL) are actually the best...
4.
Chisari C, Aguglia U, Amato M, Bergamaschi R, Bertolotto A, Bonavita S, et al.
Neurotherapeutics
. 2024 May;
21(4):e00363.
PMID: 38714462
Treatment options for secondary progressive MS (SPMS) are limited, especially considering that the new drugs recently approved are licensed for actively relapsing patients. We aimed to compare the disability progression...
5.
Bianchi A, Matranga D, Patti F, Maniscalco L, Pilotto S, Di Filippo M, et al.
J Neurol
. 2024 Feb;
271(5):2182-2194.
PMID: 38366072
Objective: Multiple sclerosis (MS) is a complex disorder in which environmental and genetic factors interact modifying disease risk and course. This multicentre, case-control study involving 18 Italian MS Centres investigated...
6.
Cerebrospinal fluid neurofilament light chains predicts early disease-activity in Multiple Sclerosis
Toscano S, Oteri V, Chisari C, Finocchiaro C, Lo Fermo S, Valentino P, et al.
Mult Scler Relat Disord
. 2023 Nov;
80:105131.
PMID: 37951096
Background: Among biomarkers of axonal damage, neurofilament light chains (NFL) seem to play a major role, representing a promising and interesting tool in Multiple Sclerosis (MS). Our aim was to...
7.
Bonaldo B, Casile A, Montarolo F, Bertolotto A
J Vis Exp
. 2023 Oct;
(200).
PMID: 37902312
Multiple Sclerosis (MS) is a chronic autoimmune inflammatory disease affecting the central nervous system (CNS). It is characterized by different prevalence in the sexes, affecting more women than men, and...
8.
Giordano A, Testa S, Bassi M, Cilia S, Bertolotto A, Quartuccio M, et al.
Health Qual Life Outcomes
. 2023 Jun;
21(1):61.
PMID: 37357308
Background: The Multiple Sclerosis Quality of Life-54 (MSQOL-54) is one of the most commonly-used MS-specific health-related quality of life (HRQOL) measures. It is a multidimensional, MS-specific HRQOL inventory, which includes...
9.
Bruschi N, Malentacchi M, Malucchi S, Sperli F, Martire S, Sala A, et al.
Neurol Ther
. 2023 May;
12(4):1375-1383.
PMID: 37166677
Introduction: B-cell-depleting agents have been widely used for neuromyelitis optica spectrum disorder (NMOSD) and MOG-associated diseases (MOGAD), but no consensus exists on the optimal dose and frequency of treatment administration....
10.
Landi D, Bovis F, Grimaldi A, Annovazzi P, Bertolotto A, Bianchi A, et al.
J Neurol Neurosurg Psychiatry
. 2022 Sep;
PMID: 36180219
Objective: Assessing the risk of clinical and radiological reactivation during pregnancy and post partum in women with multiple sclerosis (MS) treated with natalizumab (NTZ) throughout pregnancy (LONG_EXP) compared with women...